Market closed
Aprea Therapeutics Inc./$APRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Ticker
$APRE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
8
Website
APRE Metrics
BasicAdvanced
$8.7M
-
-$2.35
1.62
-
Price and volume
Market cap
$8.7M
Beta
1.62
52-week high
$2.79
52-week low
$1.52
Average daily volume
27K
Financial strength
Current ratio
7.015
Quick ratio
6.799
Management effectiveness
Return on assets (TTM)
-38.39%
Return on equity (TTM)
-66.65%
Valuation
Price to revenue (TTM)
5.794
Price to book
0.45
Price to tangible book (TTM)
0.45
Price to free cash flow (TTM)
-0.641
Growth
Revenue change (TTM)
157.63%
Earnings per share change (TTM)
-40.45%
3-year earnings per share growth (CAGR)
-59.30%
APRE News
AllArticlesVideos
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
GlobeNewsWire·2 weeks ago
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewsWire·3 weeks ago
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aprea Therapeutics Inc. stock?
Aprea Therapeutics Inc. (APRE) has a market cap of $8.7M as of April 16, 2025.
What is the P/E ratio for Aprea Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Aprea Therapeutics Inc. (APRE) stock is 0 as of April 16, 2025.
Does Aprea Therapeutics Inc. stock pay dividends?
No, Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Aprea Therapeutics Inc. dividend payment date?
Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aprea Therapeutics Inc.?
Aprea Therapeutics Inc. (APRE) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.